1. Home
  2. MYO vs FLNA Comparison

MYO vs FLNA Comparison

Compare MYO & FLNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Myomo Inc.

MYO

Myomo Inc.

HOLD

Current Price

$1.23

Market Cap

63.8M

Sector

Health Care

ML Signal

HOLD

FLNA

Filana Therapeutics Inc. Common Stock

BUY

Current Price

$0.65

Market Cap

61.8M

Sector

Health Care

ML Signal

BUY

Company Overview

Basic Information
Metric
MYO
FLNA
Founded
2004
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
63.8M
61.8M
IPO Year
2017
2000

Fundamental Metrics

Financial Performance
Metric
MYO
FLNA
Price
$1.23
$0.65
Analyst Decision
Strong Buy
Buy
Analyst Count
5
2
Target Price
$4.64
★ $6.50
AVG Volume (30 Days)
247.3K
★ 702.8K
Earning Date
11-09-2026
11-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
★ N/A
N/A
Revenue
★ $1,000,000,000.00
$41,119,000.00
Revenue This Year
$11.43
N/A
Revenue Next Year
$12.29
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 40814.79
N/A
52 Week Low
$0.61
$0.64
52 Week High
$1.89
$2.03

Technical Indicators

Market Signals
Indicator
MYO
FLNA
Relative Strength Index (RSI) 37.29 34.93
Support Level $1.18 N/A
Resistance Level $1.75 $1.05
Average True Range (ATR) 0.11 0.04
MACD -0.02 -0.02
Stochastic Oscillator 6.67 3.74

Price Performance

Historical Comparison
MYO
FLNA

About MYO Myomo Inc.

Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The company provides the devices to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics providers for which a fee is paid. The company sells the product to orthotics and prosthetics providers around the world and the Veterans Health Administration (VA). Geographically, it derives maximum revenue from the United States, followed by Germany, and other international.

About FLNA Filana Therapeutics Inc. Common Stock

Filana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.

Share on Social Networks: